A share price of Nektar Therapeutics [NKTR] is currently trading at $1.46, up 5.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The NKTR shares have gain 4.29% over the last week, with a monthly amount glided 33.94%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on June 28, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $2. On November 09, 2023, upgrade upgraded it’s rating to Outperform. Jefferies upgraded its rating to a Hold and decreased its price target to $1 on May 10, 2023. Jefferies downgraded its rating to a Underperform and reduced its price target to $1.50 on February 24, 2023. JP Morgan downgraded its rating to Underweight for this stock on August 08, 2022.
Nektar Therapeutics experienced fluctuations in its stock price throughout the past year between $0.41 and $1.93. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $1.46 at the most recent close of the market. An investor can expect a potential return of 1047.26% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Trailing Twelve Months sales for Nektar Therapeutics [NASDAQ:NKTR] were 90.17M which represents 0.21% growth. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -1.78%, Pretax Profit Margin comes in at -1.95%, and Net Profit Margin reading is -1.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -1.15 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3967 points at the first support level, and at 1.3333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5067, and for the 2nd resistance point, it is at 1.5533.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nektar Therapeutics [NASDAQ:NKTR] is 6.10. On the other hand, the Quick Ratio is 5.79, and the Cash Ratio is 0.66. Considering the valuation of this stock, the price to sales ratio is 2.98, the price to book ratio is 2.12.
Transactions by insiders
Recent insider trading involved CHESS ROBERT, Director, that happened on Jun 14 ’24 when 19500.0 shares were sold. President & CEO, ROBIN HOWARD W completed a deal on May 17 ’24 to sell 16650.0 shares. Meanwhile, Chief R&D Officer Zalevsky Jonathan sold 7355.0 shares on May 17 ’24.
